Theratope vaccine

Theratope® vaccine

Oncology A synthetic vaccine designed to stimulate the immune system to combat metastatic breast, colorectal and other CAs. See Therapeutic vaccine.
References in periodicals archive ?
Biomira's lead product, THERATOPE vaccine, is currently in a Phase III trial for women with metastatic breast cancer.
The company's lead product candidate, THERATOPE vaccine, also has broad potential for immunotherapy of cancers.
(Edmonton, Canada; 403-490-2818) announced that the company was issued a patent from the United States Patent and Trademark Office on August 25, 1998, for technology used in its THERATOPE vaccine. The patent, number 5,798,090, covers enhancing cellular immunity by administering a synthetic conjugate of a carbohydrate epitope and an immunogenic carrier.
In Phase II clinical trials, patients with metastatic breast cancer appeared to show a survival benefit associated with the use of THERATOPE vaccine. A larger, Phase III multinational clinical trial is scheduled to begin in the fourth quarter of 1998.